JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: MK-8931 (also known as Verubecestat or SCH 900931) is a beta-secretase 1 and BACE1 inhibitor that is in Phase 3 clinical trial for treatment of Alzheimer's disease. Amyloidogenic pathway in Alzheimer's disease (AD) involves breakdown of APP by beta-secretase followed by gamma-secretase and results in formation of amyloid beta plaque. beta-secretase has been a promising target for developing novel anti-Alzheimer drugs.MK-8931 binds significantly to beta-secretase. target: BACE1. In vitro:MK-8931 can effectively reduce Abeta40 in cells with a Ki of 7.8 nM and an IC50 of 13 nM. Docking revealed that, with respect to their free binding energy, acylguanidine 7a has the lowest binding energy followed by MK-8931 and pioglitazone and binds significantly to beta-secretase.
References: Transl Neurodegener. 2016 Jul 14; 5:13; Adv Bioinformatics. 2016; 2016:9258578.
Related CAS#:1875153-95-9 (Tosylate); 1970144-54-7 (HBr); 1897370-45-4 (hydrate); 2095432-65-6 (TFA)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!